Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHA:688393)
China · Delayed Price · Currency is CNY 18.37
+0.46 (2.57%)
Aug 3, 2026, 11:29 AM CST
SHA:688393 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,676 | 2,217 | 1,620 | 2,336 | 2,053 | 2,844 | |
Market Cap Growth | -42.28% | 36.86% | -30.68% | 13.78% | -27.80% | -17.60% |
Enterprise Value | 1,354 | 1,940 | 1,498 | 2,207 | 1,734 | 2,081 |
Last Close Price | 17.91 | 23.58 | 17.17 | 24.54 | 21.50 | 29.40 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 76.07 | 58.33 | 48.10 | 35.65 |
PS Ratio | 4.77 | 6.44 | 3.44 | 4.70 | 4.05 | 6.48 |
PB Ratio | 1.45 | 1.91 | 1.32 | 1.89 | 1.68 | 2.35 |
P/TBV Ratio | 1.49 | 1.93 | 1.32 | 1.90 | 1.72 | 2.43 |
P/FCF Ratio | - | 131.43 | - | - | - | - |
P/OCF Ratio | 96.81 | 55.39 | 457.11 | 136.46 | 211.34 | 47.71 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.85 | 5.63 | 3.18 | 4.44 | 3.42 | 4.74 |
EV/EBITDA Ratio | - | - | 43.14 | 48.25 | 32.22 | 27.63 |
EV/EBIT Ratio | - | - | - | 292.63 | 80.72 | 35.40 |
EV/FCF Ratio | - | 115.00 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 |
Debt / EBITDA Ratio | - | - | 0.29 | 0.58 | 0.43 | 0.16 |
Debt / FCF Ratio | - | 0.18 | - | - | - | - |
Net Debt / Equity Ratio | -0.26 | -0.23 | -0.11 | -0.07 | -0.20 | -0.52 |
Net Debt / EBITDA Ratio | 20.02 | 9.73 | -4.03 | -2.01 | -4.49 | -8.29 |
Net Debt / FCF Ratio | 47.82 | -15.57 | 6.97 | 4.45 | 3.87 | 7.46 |
Asset Turnover | 0.27 | 0.26 | 0.34 | 0.36 | 0.37 | 0.33 |
Inventory Turnover | 1.40 | 1.51 | 2.00 | 2.35 | 2.88 | 3.01 |
Quick Ratio | 7.61 | 5.37 | 4.71 | 3.35 | 4.46 | 7.99 |
Current Ratio | 9.43 | 7.34 | 8.19 | 5.14 | 5.21 | 8.51 |
Return on Equity (ROE) | -3.39% | -4.25% | 1.21% | 1.71% | 2.41% | 6.33% |
Return on Assets (ROA) | -2.63% | -3.13% | -0.21% | 0.34% | 0.97% | 2.77% |
Return on Invested Capital (ROIC) | -6.19% | -6.68% | -0.41% | 0.71% | 2.74% | 11.00% |
Return on Capital Employed (ROCE) | -4.50% | -5.50% | -0.40% | 0.60% | 1.70% | 4.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.26% | -2.12% | 1.31% | 1.71% | 2.08% | 2.80% |
FCF Yield | -0.37% | 0.76% | -1.24% | -0.88% | -3.04% | -2.94% |
Dividend Yield | 0.56% | 0.42% | 0.58% | 0.61% | 0.65% | 0.92% |
Payout Ratio | - | - | 68.14% | 33.62% | 62.34% | 33.00% |
Buyback Yield / Dilution | -0.53% | -1.59% | 2.94% | -0.53% | -1.09% | -20.71% |
Total Shareholder Return | 0.02% | -1.17% | 3.52% | 0.09% | -0.44% | -19.80% |